Ezetimibe/simvastatin: the elite LDL-cholesterol lowering entity?

    loading  Checking for direct PDF access through Ovid

Abstract

Ezetimibe/simvastatin [Vytorin] is more effective than rosuvastatin [Crestor] in lowering LDL-cholesterol levels in patients with primary hypercholesterolaemia, according to new data presented at the 14th International Symposium on Atherosclerosis (ISA) [Rome, Italy; June 2006]. Conducted in 2855 patients, ezetimibe/simvastatin provided significantly greater LDL-cholesterol lowering efficacy than rosuvastatin at all dose comparisons, and averaged across all doses, at 6 weeks. In a subgroup analysis of 715 high-risk patients, a significantly greater proportion of patients treated with ezetimibe/simvastatin than rosuvastatin attained the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III LDL-cholesterol target of < 100 mg/dL. Furthermore, more than one half of patients treated with ezetimibe/simvastatin achieved an optional LDL-cholesterol target of < 70 mg/dL, compared with less than one-third of rosuvastatin recipients.

Related Topics

    loading  Loading Related Articles